Carthera
Lyon, FR · Founded 2010 · 35 employees on LinkedIn · 2 known investors
Carthera develops SonoCloud®, an implantable ultrasound device that temporarily disrupts the blood-brain barrier to improve drug delivery to the brain for treatment of brain diseases including glioblastoma, brain metastases, and Alzheimer's Disease. The company's technology uses low-intensity pulsed ultrasound combined with microbubbles to increase therapeutic efficacy of existing and new therapies.
Founders & leadership
Carthera was founded in 2010 by Alexandre Carpentier.
AC
Alexandre CarpentierinFounder
Investors · 2
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BDec 2023Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Carthera do?
- Carthera develops SonoCloud®, an implantable ultrasound device that temporarily disrupts the blood-brain barrier to improve drug delivery to the brain for treatment of brain diseases including glioblastoma, brain metastases, and Alzheimer's Disease. The company's technology uses low-intensity pulsed ultrasound combined with microbubbles to increase therapeutic efficacy of existing and new therapies.
- Who founded Carthera?
- Carthera was founded by Alexandre Carpentier in 2010.
- Who are Carthera's investors?
- Carthera's investors include Supernova, Supernova Invest.
- Where is Carthera headquartered?
- Carthera is headquartered in Lyon, FR.